Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. Previously, we found an anxiolytic effect of ziprasidone augmentation to escitalopram (compared with placebo augmentation) in patients with depression in an 8-week, randomized, double-blind, parallel-group, placebocontrolled trial. Here, we carried out a post-hoc analysis, comparing changes in the Hamilton Depression and Anxiety Rating Scales between patients with anxious depression versus nonanxious depression, using a moderator analysis. Hamilton Depression Rating Scales total change scores from baseline and endpoint were not significantly different (interaction term P=0.91) in patients with anxious depression on ziprasidone augmentation (n=19; -9.1± 4.9) or placebo (n=19; -6.1± 8.9) versus patients without anxious depression on ziprasidone (n=52; -5.5± 6.7) or placebo (n=49; -2.3± 4.5). There was a trend toward statistical significance (interaction term P=0.1) in favor of patients without anxious depression for a difference in Hamilton Anxiety Rating Scale total change scores from baseline to endpoint [patients with anxious depression on ziprasidone augmentation (n=19; -2.7± 5.3) or placebo (n=19; -3.3± 5.8) versus patients without anxious depression on ziprasidone (n=51; -3.9± 6.6) or placebo (n=44; -0.9 ±4.7)]. Ziprasidone augmentation was equally efficacious in treating depression in patients with versus without anxious depression. However, the observed anxiolytic effect for patients with higher anxiety was not clinically significant.